Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension.

Introduction: Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles.

Objective: To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.

Diode laser trabeculoplasty in open angle glaucoma: 50 micron vs. 100 micron spot size.

The study was aimed at evaluating the efficacy of diode laser trabeculoplsaty in lowering intraocular pressure in patients with both primary open-angle glaucoma and exfoliation glaucoma by using different size of laser spot. This six-month, unmasked, controlled, prospective study included sixty-two patients with the same number of eyes, who were divided into two groups. Trabeculoplasty was performed with 50 micron and 100 micron laser spot size in the group I and group II, respectively.

[Adjunctive therapy with brinzolamide in patients on travoprost treatment].

Introduction: This study was aimed at evaluating the safety and efficacy of brinzolamide 1% suspension (Azopt 1%) and travoprost 0.004% (Travatan) combined therapy in patients with open-angle glaucoma or ocular hypertension who are in need of additional intraocular pressure lowering.

Material And Methods: This is a prospective, three-month, open-label, clinical study.

A comparison of 180 degrees of treatment with diode laser trabeculoplasty in primary open-angle glaucoma and exfoliation glaucoma: a short-term study of 22 patients.

Purpose: Evaluation of diode laser trabeculoplsaty (DLT) efficacy in lowering intraocular pressure (IOP) in patients with open-angle glaucoma and the differences between primary open-angle glaucoma (POAG) and exfoliation glaucoma (XFG) after it; estimation of the shortest period after DLT when a decrease of IOP can be detected; estimation of the shortest period in achieving a maximum IOP decreases after which no further changes could be expected.

Materials And Methods: A three-month, open-labeled, controlled, prospective study on the IOP-lowering efficacy of DLT in patients with POAG and XFG was performed between November 2007 and January 2008. Thirty-one eyes (POAG 19, XFG 12) were enrolled.